摘要
目的研究从葛根芩连丸中筛选出的小檗碱(Ber)和汉黄芩素(Wog)的不同比例组合物对伊立替康(CPT-11)抗结直肠癌(CRC)疗效的增强作用。方法以Ber和Wog在葛根芩连丸中的含量摩尔比为基准,评价系列比例组合物在体外对CPT-11的增效活性,筛选最优配比组合。构建裸鼠皮下移植瘤模型,验证最优配比组合物的体内增效作用。结果体外实验结果表明Ber和Wog摩尔比为1∶1时对CPT-11的增效作用最优。体内实验结果表明该组合物能够协同增强CPT-11的体内抗肿瘤活性(金正均Q=1.16)。结论Ber和Wog摩尔比为1∶1的组合物可在体内外协同增强化疗药物CPT-11的抗CRC活性,相关研究结果可为临床上进一步开发Ber和Wog组合物作为抗CRC药物奠定基础。
Objectivee To explore the synergistic effect of different combinations of berberine(Ber)and wogonin(Wog)identified from Gegen Qinlian Pill in enhancing the anticancer efficacy of irinotecan(CPT-1l)against colorectal cancer(CRC).Methods Based on the molar ratio of Ber and Wog in Gegen Qinlian Pill,a series of combinations with different ratios were evaluated for their in vitro synergistic effects on CPT-11.The optimal combination was selected.Furthermore,a subcutaneous tumor-bearing mouse model was established to verify the in vivo synergistic effect of the optimal combination.Results In vitro experiments indicated that the optimal synergistic effect of Ber and Wog on CPT-1l was achieved at a molar ratio of 1:1.In vivo results showed that this combination could synergistically enhance the antitumor activity of CPT-11(Q=1.16).Conclusion The combination of Ber and Wog in a 1:1 molar ratio can synergistically enhance the anti-cancer activity of the chemotherapeutic drug CPT-11 both in vitro and in vivo.These findings lay the foundation for further clinical development of Ber and Wog combinations as potential therapeutic agents for CRC.
作者
胡丁欣
张颖
张尊建
张培
许风国
HU Dingxin;ZHANG Ying;ZHANG Zunjian;ZHANG Pei;XU Fengguo(School of Pharmacy,China Pharmaceutical University,Nanjing 210009,China;School of Traditional Chinese Pharmacy,China Pharmaceutical University,Nanjing 210009,China)
出处
《现代中药研究与实践》
2025年第2期17-23,共7页
Research and Practice on Chinese Medicines
基金
国家自然科学基金项目(82104117,82173947)。
